论文部分内容阅读
目的观察四联疗法治疗幽门螺杆菌相关性慢性胃炎的临床疗效及安全性。方法 120例幽门螺杆菌相关性慢性胃炎患者按照治疗方法不同分为治疗组(四联疗法)63例与对照组(三联疗法)57例,均连续治疗2周为1个疗程,比较2组临床疗效。结果连续治疗2周后,治疗组愈显率为81%,对照组愈显率为72%,治疗组愈显率明显高于对照组(P<0.05);治疗组腹胀腹痛、恶心呕吐及反酸改善率均明显高于对照组(P均<0.05);治疗组H.pylori阴性率为73%,对照组为60%,治疗组H.pylori根除率明显高于对照组(P<0.05);2组患者不良反应发生率比较无显著性差异。结论四联疗法治疗幽门螺杆菌相关性慢性胃炎效果理想,值得推广应用。
Objective To observe the clinical efficacy and safety of quadruple therapy in the treatment of Helicobacter pylori associated chronic gastritis. Methods 120 patients with Helicobacter pylori-related chronic gastritis were divided into treatment group (63 cases) and control group (57 cases), 57 cases were treated with continuous treatment for 2 weeks. According to the different treatment methods, two groups of clinical Efficacy. Results After 2 weeks of continuous treatment, the cure rate of the treatment group was 81% and that of the control group was 72%. The cure rate of the treatment group was significantly higher than that of the control group (P <0.05). The abdominal distension, nausea and vomiting, (P <0.05). The negative rate of H.pylori in the treatment group was 73% and that in the control group was 60%. The H.pylori eradication rate in the treatment group was significantly higher than that in the control group (P <0.05) There was no significant difference between the two groups in the incidence of adverse reactions. Conclusion The quadruple therapy is effective in treating Helicobacter pylori associated chronic gastritis and is worthy of promotion and application.